Dr. Byrareddy’s COVID-19 Research

Summary
Publications
In the news
Videos
Lectures and talks
Current funding


Summary

The dedicated researchers of Dr. Byrareddy’s lab, in collaboration with colleagues around the world, are working to understand and fight SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Lab research topics of interest include the determination of a mechanism to inhibit SARS-CoV-2 viral replication and new treatment discoveries. The laboratory is currently investigating the pathophysiology of COVID-19 and developing therapeutics to treat/reduce the disease in general. Developments build on previous areas of inquiry and also explore new fields of study. The following publications highlight the lab’s work specific to COVID-19 and SARS-CoV-2:


Publications

  1. Devadoss D, Acharya A, Manevski M, Pandey K, Borchert GM, Nair M, Mirsaeidi M, Byrareddy SN, Chand HS. Distinct Mucoinflammatory Phenotype and the Immunomodulatory Long Noncoding Transcripts Associated with SARS-CoV-2 Airway Infection. medRxiv [Preprint]. 2021 May 18:2021.05.13.21257152. doi: 10.1101/2021.05.13.21257152. PMID: 34031668; PMCID: PMC8142670.

  2. Saccon E, Chen X, Mikaeloff F, Rodriguez JE, Szekely L, Vinhas BS, Krishnan S, Byrareddy SN, Frisan T, Végvári Á, Mirazimi A, Neogi U, Gupta S. Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2. iScience. 2021 May 21;24(5):102420. doi:  10.1016/j.isci.2021.102420. Epub 2021 Apr 20. PMID: 33898942; PMCID: PMC8056843.

  3. Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Lorson CL, Singh K, Byrareddy SN. Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors. bioRxiv [Preprint]. 2021 Apr 2:2021.04.02.438204. doi: 10.1101/2021.04.02.438204. PMID: 33821265; PMCID: PMC8020965.

  4. Patel RH, Acharya A, Chand HS, Mohan M, Byrareddy SN. Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges. AIDS Res Hum Retroviruses. 2021 Apr;37(4):266-282. doi: 10.1089/AID.2020.0284. Epub 2021 Mar 23. PMID: 33599163; PMCID: PMC8035919.

  5. Spratt AN, Kannan SR, Woods LT, Weisman GA, Quinn TP, Lorson CL, Sönnerborg A, Byrareddy SN, Singh K. Factors Associated with Emerging and Re-emerging of SARS-CoV-2 Variants. bioRxiv [Preprint]. 2021 Mar 24:2021.03.24.436850. doi: 10.1101/2021.03.24.436850. PMID: 33791700; PMCID: PMC8010727.

  6. Acharya A, Pandey K, Thurman M, Challagundala KB, Vann KR, Kutateladze TG, Morales GA, Durden DL, Byrareddy SN. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor. bioRxiv [Preprint]. 2021 Mar 5:2021.03.02.433604. doi: 10.1101/2021.03.02.433604. PMID: 33688653; PMCID: PMC7941624.

  7. Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics. 2021 Jan 1;11(2):731-753. doi: 10.7150/thno.51471. PMID: 33391502; PMCID: PMC7738845.

  8. Husain A, Byrareddy SN. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Chem Biol Interact. 2020 Nov 1;331:109282. DOI: 10.1016/j.cbi.2020.109282
  9. Response to “Epidemiology and transmission dynamics of COVID-19 in two Indian states” https://science.sciencemag.org/content/370/6517/691/tab-e-letters Science. 2020 Nov 6: DOI: 10.1126/science.abd7672

  10. Tiwari R, Mishra AR, Mikaeloff F, Gupta S, Mirazimi A, Byrareddy SN, Neogi U, Nayak D. In silico and In vitro Studies Reveal Complement System Drives Coagulation Cascade in SARS-CoV-2 Pathogenesis. Comput Struct Biotechnol J. 2020 Nov 11. DOI: 10.1016/j.csbj.2020.11.005

  11. Pandey K, Acharya A, Mohan M, Ng CL, Reid PS, Byrareddy SN. Animal Models for SARS-CoV-2 research: A Comprehensive Literature Review. Transbound Emerg Dis. 2020 Oct 31. DOI: 10.1111/tbed.13907

  12. Trivedi, J.; Mohan, M.; Byrareddy, S.N. Drug Repurposing Approaches to Combating Viral Infections. J. Clin. Med. 20209, 3777. https://www.mdpi.com/2077-0383/9/11/3777

  13. Pathania AS, Prathipati P, Abdul BAA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics 2021; 11(2):731-753. doi:10.7150/thno.51471. Available from https://www.thno.org/v11p0731.htm 

  14. Kannan SR, Spratt AN, Quinn TP, Heng X, Lorson CL, Sönnerborg A, Byrareddy SN, Singh K. Infectivity of SARS-CoV-2: there Is Something More than D614G? Neuroimmune Pharmacol. 2020 Sep 15. doi: 10.1007/s11481-020-09954-3. Epub ahead of print. PMID: 32930936.

  15. Rothan HA, Byrareddy SN. The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Pediatr Allergy Immunol. 2020 Sep 8. doi: 10.1111/pai.13361. Epub ahead of print. PMID: 32897642.

  16. Rothan HA, Acharya A, Reid SP, Kumar M, Byrareddy SN. Molecular Aspects of COVID-19 Differential Pathogenesis. Pathogens. 2020 Jul 6;9(7):E538. doi: 10.3390/pathogens9070538. PMID: 32640525.

  17. Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. SARS-CoV-2 Infection Leads to Neurological Dysfunction. J Neuroimmune Pharmacol. 2020 Jun;15(2):167-173. doi: 10.1007/s11481-020-09924-9. Epub 2020 May 23. PMID: 32447746; PMCID: PMC7244399.

  18. Neogi U, Hill KJ, Ambikan AT, Heng X, Quinn TP, Byrareddy SN, Sönnerborg A, Sarafianos SG, Singh K. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. Pathogens. 2020 Apr 26;9(5):320. doi: 10.3390/pathogens9050320. PMID: 32357471; PMCID: PMC7281371.

  19. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26. PMID: 32113704; PMCID: PMC7127067.

  20. Byrareddy SN, Mohan M. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Brain Behav Immun. 2020 Jul;87:120-121. doi: 10.1016/j.bbi.2020.04.079. Epub 2020 Apr 28. PMID: 32360437; PMCID: PMC7187842.

  21. Singu S, Acharya A, Challagundla KB, Byrareddy SN. Impact of Social determinants of health on the emerging COVID-19 pandemic in the United States. Front Public Health 2020, 8:406. doi=10.3389/fpubh.2020.00406.

  22. Mishra PK, Tandon R, Byrareddy SN. Diabetes and COVID-19 risk: a miRNA perspective. Am J Physiol Heart Circ Physiol. 2020 Aug 7. doi: 10.1152/ajpheart.00489.2020. Epub ahead of print. PMID: 32762561.

  23. Patel RH, Acharya A, Mohan M, Byrareddy SN. COVID-19 and AIDS: outcomes from the co-existence of two global pandemics and the importance of chronic antiretroviral therapy. J Med Virol. 2020 Aug 11. doi: 10.1002/jmv.26416. Epub ahead of print. PMID: 32779740.

  24. Olwenyi OA, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Ng CL, Reid SP, Byrareddy SN. Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). J Mol Med. 2020 Aug 18. doi.org/10.1007/s00109-020-01961-4


In the news

Epidemiology, etiology, pathogenesis, and treatment of COVID-19

News Medical Life Sciences | April 5, 2021
Researchers Identify potent small molecule inhibitors against SARS-CoV-2

India Science Wire | March 22, 2021
Researchers identify drug that can be repurposed to treat COVID-19

NDTV | March 22, 2021
Researchers Identify Drug That Can Be Repurposed To Treat COVID-19

Biospectrum | March 22, 2021
IISER Bhopal, Nebraska University suggest repurposing Rapamycin to treat COVID-19

News Medical Life Sciences | March 4, 2021
Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Newsweek | January 14, 2021
Lockdown Effectiveness Starts with Relief for Everyday Americans

Science Daily | December 21, 2020
Traditional model for disease spread may not work in COVID-19

Times of India | November 16, 2020
"IISER-Bhopal, Nebraska varsity suggest drug for Covid-19"

World Health Organization
COVID-19: Global literature on coronavirus disease

UNMC Newsroom | October 2, 2020
"Paper suggests cause for COVID-19's aftereffects in children"

Elsevier | May 2020
Highlighted Article: “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak”

The Journal of the San Juan Islands | May 25, 2020
"Coronavirus: the known and the unknown"

SciTechDaily | May 11, 2020
"Veterinary Medicine Researcher Identifies Four Possible Treatments for COVID-19"

Business Insider | May 10, 2020
“As the coronavirus case curve flattens, daily deaths may stay high, experts warn”

Sciworthy | March 27, 2020
“COVID-19: What it is, how it works, and what we can do to prevent its spread”

Fatherly | March 20, 2020
A Parent’s Guide to Treating Symptoms of Coronavirus 

Medium | April 20, 2020
“A systematic review on COVID-19 — epidemiology, etiology, pathogenesis, and treatment”

Social determinants of health (SDOH) and COVID-19

Physician's Weekly | August 17, 2020
"Impact of Social Determinants of Health on the Emerging COVID-19 Pandemic in the United States"

UNMC Newsroom | July 29, 2020
"Paper highlights COVID-19 disparities"

Cannabinoids, cannabidiol (CBD), and COVID-19

Elements of Green | September 10, 2020
COVID-19 and CBD

Forbes | August 20, 2020
"Synthetic Cannabinoid Drug For Covid-19 Approved For Phase-1 Clinical Trials"

Spectrum Labs | August 6, 2020
“Siddappa Byrareddy, PhD – Can CBD reduce lung inflammation due to COVID-19?”

Forbes | July 21, 2020
"New Research Suggests Terpenes And CBD Work 2X’s Better For Covid-19 Inflammation Than Corticosteroid"

WBTV (CBS News) | July 18, 2020
"Researchers look into cannabis as a potential COVID-19 treatment"

Whole Foods Magazine | July 10, 2020
"Researchers note potential of CBD as COVID-19 treatment option"

Brendan Bures, Chicago Tribune | July 9, 2020
Chicago Tribune: CBD coronavirus treatment research

The Fresh Toast | July 9, 2020
"Researchers Say CBD Could Provide Vital Treatment For COVID-19"

High Times | July 8, 2020
“Researchers looking at CBD to treat COVID-19 lung inflammation”

iHeart Radio | July 7, 2020
“Cannabis May Reduce Deadly COVID-19 Lung Inflammation”

Forbes | July 6, 2020
"Cannabis may reduce deadly COVID-19 lung inflammation, researchers explain why"

Natural Blaze | July 2020
“Researchers Suggest Cannabis Derived CBD Could Help Reduce Deadly COVID-19 Lung Inflammation”

Debug Lies News | June 22, 2020
"Israeli researchers say medical Cannabis could be used to treating some symptoms of seriously ill COVID-19 patients"

Open Access Government | June 17, 2020
"Cannabinoids in medicine part 5: Treating COVID-19"

Kurativecbd | May 27, 2020
Could CBD be helpful in the fight against COVID-19?

Videos

CROI Webinar | 2021
Novel Treatments For SARS-CoV-2: Starting At The Bench
 
Spectrum Labs: The Help Startup Journey | Aug. 6, 2020
"#17. Siddappa Byrareddy, PhD - Can CBD reduce lung inflammation due to COVID-19? (podcast)"

AOL | July 24, 2020
"Could CBD help fight severe cases of COVID-19?"

Newsy | July 24, 2020
"Could CBD help fight severe cases of COVID-19?"

CBS News | July 18, 2020
"Researchers look into cannabis as a potential COVID-19 treatment"

ABC 7 (Los Angeles, CA) | July 9, 2020
"Scientists researching whether cannabis could help reduce lung inflammation from COVID-19"


Lectures and talks on COVID-19 (2020-2021)

  1. 2021:Invited Speaker, COVID/SARS CoV2 Rapid Research Reports #6, Cold Spring Harbor Laboratory, July  7-8, 2021.
  2. 2021: Invited Speaker, COVID-19 workshop, Society of Neuroimmune Pharmacology, April, 9th
  3. 2021: Invited Speaker, Veterans Health Administration- VA.gov, University of Nebraska Medical Center 
  4. 2021: Invited Speaker, University of Tennessee Health Science Center-College of Pharmacy. February.
  5. 2020: Keynote Speaker, Virology Webinar 2020, International E-Conference on Virology, infectious diseases and COVID-19. December 7-8.
  6. 2020: Invited Speaker, UNMC College of Medicine Research Retreat, UNMC, November 11-12.
  7. 2020: Invited Speaker, College of Biological Sciences (CBS), University of California, Davis, October 26.
  8. 2020: Invited Speaker, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, October 5.
  9. 2020: Invited Speaker, Department of Biochemistry, University of Missouri, September 18.
  10. 2020: Invited Speaker, CannX: 5th International Medical Cannabis Conference, Tel Aviv on October 26-27.
  11. 2020: Keynote Speaker, Webinar Symposium on COVID-19, Tirupati Mahaila University, India, May 21.

Current funding